NADPH氧化酶2在恶性肿瘤中的研究进展

doi:10.3760/cma.j.cn371439-20230428-00117

国际肿瘤学杂志 ›› 2023, Vol. 50 ›› Issue (10): 618-621.doi: 10.3760/cma.j.cn371439-20230428-00117

NADPH氧化酶2在恶性肿瘤中的研究进展

刘小洁¹^,², 黄俊星¹()

¹南京医科大学附属泰州人民医院/泰州市人民医院肿瘤科，泰州 225300
²大连医科大学临床医学系，大连 116000

收稿日期:2023-04-28 修回日期:2023-07-28 出版日期:2023-10-08 发布日期:2023-11-08
通讯作者: 黄俊星 E-mail:hjxtz@sina.cn
基金资助:
江苏省卫生健康委科研项目(BJ20012);江苏省医学创新团队项目(CXTDA2017042);泰州市科技支撑计划（社会发展）项目(TS202001)

Research progress of NADPH oxidase 2 in malignant tumors

Liu Xiaojie¹^,², Huang Junxing¹()

¹Department of Oncology， Affiliated Jiangsu Taizhou People's Hospital of Nanjing Medical University， Jiangsu Taizhou People's Hospital， Taizhou 225300， China
²Department of Clinical Medicine， Dalian Medical University， Dalian 116000， China

Received:2023-04-28 Revised:2023-07-28 Online:2023-10-08 Published:2023-11-08
Contact: Huang Junxing E-mail:hjxtz@sina.cn
Supported by:
Jiangsu Commission of Health Research Project(BJ20012);Jiangsu Provincial Medical Innovation Team Project(CXTDA2017042);Taizhou Science and Technology Support Plan（Social Development）Project(TS202001)

摘要/Abstract

摘要：

还原型烟酰胺腺嘌呤二核苷酸磷酸（NADPH）氧化酶2（Nox2）通过产生活性氧参与及影响人体正常生理功能。目前已发现Nox2在急性髓系白血病、胃癌、结直肠癌、卵巢癌、肺癌、食管癌中与患者的预后、肿瘤抗药性、分子靶向治疗等相关，有可能是恶性肿瘤新的生物标志物及潜在的治疗靶点。

关键词: NADPH氧化酶2, 肿瘤, 活性氧, 抗药性，肿瘤, 预后

Abstract:

Reduced nicotinamide adenine dinucleotide phosphate （NADPH） oxidase 2 （Nox2） acts as a source of reactive oxygen species， which participates in and influences normal physiological function of human body. Nowadays， many studies have found that Nox2 is related to prognosis of patients， drug resistance and molecular targeted therapy in various malignant tumors， such as acute myeloid leukemia， gastric cancer， colorectal cancer， ovarian cancer， lung cancer and esophageal cancer. What's more， it may be a novel biomarker and a potential therapeutic target for malignant tumors.

Key words: NADPH oxidase 2, Neoplasms, Reactive oxygen species, Drug resistance， neoplasm, Prognosis

刘小洁, 黄俊星. NADPH氧化酶2在恶性肿瘤中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(10): 618-621.

Liu Xiaojie, Huang Junxing. Research progress of NADPH oxidase 2 in malignant tumors[J]. Journal of International Oncology, 2023, 50(10): 618-621.

参考文献 30

[1]	Grauers Wiktorin H, Aydin E, Hellstrand K, et al. NOX2-derived reactive oxygen species in cancer[J]. Oxid Med Cell Longev, 2020: 7095902. DOI: 10.1155/2020/7095902.
[2]	Schröder K. NADPH oxidases: current aspects and tools[J]. Redox Biol, 2020, 34: 101512. DOI: 10.1016/j.redox.2020.101512.
[3]	Vermot A, Petit-Härtlein I, Smith SME, et al. NADPH oxidases (NOX): an overview from discovery, molecular mechanisms to physiology and pathology[J]. Antioxidants (Basel), 2021, 10(6): 890. DOI: 10.3390/antiox10060890.
[4]	Xu L, Balzarolo M, Robinson EL, et al. NOX1 mediates metabolic heart disease in mice and is upregulated in monocytes of humans with diastolic dysfunction[J]. Cardiovasc Res, 2022, 118(14): 2973-2984. DOI: 10.1093/cvr/cvab349.
[5]	Mohri H, Ninoyu Y, Sakaguchi H, et al. Nox3-derived superoxide in cochleae induces sensorineural hearing loss[J]. J Neurosci, 2021, 41(21): 4716-4731. DOI: 10.1523/JNEUROSCI.2672-20.2021.
[6]	Trevelin SC, Shah AM, Lombardi G. Beyond bacterial killing: NADPH oxidase 2 is an immunomodulator[J]. Immunol Lett, 2020, 221: 39-48. DOI: 10.1016/j.imlet.2020.02.009. pmid: 32092360
[7]	Shimony S, Stahl M, Stone RM. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management[J]. Am J Hematol, 2023, 98(3): 502-526. DOI: 10.1002/ajh.26822. pmid: 36594187
[8]	Jones CL. NOX2: a determinant of acute myeloid leukemia survival[J]. Haematologica, 2022, 107(11): 2530-2531. DOI: 10.3324/haematol.2022.280677.
[9]	Paolillo R, Boulanger M, Gâtel P, et al. The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of acute myeloid leukemias[J]. Haematologica, 2022, 107(11): 2562-2575. DOI: 10.3324/haematol.2021.279889. pmid: 35172562
[10]	Ijurko C, González-García N, Galindo-Villardón P, et al. A 29-gene signature associated with NOX2 discriminates acute myeloid leukemia prognosis and survival[J]. Am J Hematol, 2022, 97(4): 448-457. DOI: 10.1002/ajh.26477. pmid: 35073432
[11]	Robinson AJ, Hopkins GL, Rastogi N, et al. Reactive oxygen species drive proliferation in acute myeloid leukemia via the glycolytic regulator PFKFB3[J]. Cancer Res, 2020, 80(5): 937-949. DOI: 10.1158/0008-5472.CAN-19-1920. pmid: 31862780
[12]	Germon ZP, Sillar JR, Mannan A, et al. Blockade of ROS production inhibits oncogenic signaling in acute myeloid leukemia and amplifies response to precision therapies[J]. Sci Signal, 2023, 16(778): eabp9586. DOI: 10.1126/scisignal.abp9586.
[13]	Cao JY, Mansouri S, Frappier L. Changes in the nasopharyngeal carcinoma nuclear proteome induced by the EBNA1 protein of Epstein-Barr virus reveal potential roles for EBNA1 in metastasis and oxidative stress responses[J]. J Virol, 2012, 86(1): 382-394. DOI: 10.1128/JVI.05648-11. pmid: 22013061
[14]	Kim SM, Hur DY, Hong SW, et al. EBV-encoded EBNA1 regulates cell viability by modulating miR34a-NOX2-ROS signaling in gastric cancer cells[J]. Biochem Biophys Res Commun, 2017, 494(3/4): 550-555. DOI: 10.1016/j.bbrc.2017.10.095.
[15]	Wang P, Shi Q, Deng WH, et al. Relationship between expression of NADPH oxidase 2 and invasion and prognosis of human gastric cancer[J]. World J Gastroenterol, 2015, 21(20): 6271-6279. DOI: 10.3748/wjg.v21.i20.6271.
[16]	Wang Z, Tang T, Wang S, et al. Aloin inhibits the proliferation and migration of gastric cancer cells by regulating NOX2-ROS-mediated pro-survival signal pathways[J]. Drug Des Devel Ther, 2020, 14: 145-155. DOI: 10.2147/DDDT.S219247.
[17]	You X, Ma M, Hou G, et al. Gene expression and prognosis of NOX family members in gastric cancer[J]. Onco Targets Ther, 2018, 11: 3065-3074. DOI: 10.2147/OTT.S161287.
[18]	Luo M, Yang X, Chen HN, et al. Drug resistance in colorectal cancer: an epigenetic overview[J]. Biochim Biophys Acta Rev Cancer, 2021, 1876(2): 188623. DOI: 10.1016/j.bbcan.2021.188623.
[19]	Banskota S, Regmi SC, Kim JA. NOX1 to NOX2 Switch deactivates AMPK and induces invasive phenotype in colon cancer cells through overexpression of MMP-7[J]. Mol Cancer, 2015, 14: 123. DOI: 10.1186/s12943-015-0379-0. pmid: 26116564
[20]	Takiguchi K, Shimizu H, Shoda K, et al. The expression and role of NADPH oxidase 2 in colon cancer[J]. Anticancer Res, 2023, 43(6): 2601-2608. DOI: 10.21873/anticanres.16427. pmid: 37247898
[21]	Guo Y, Han B, Luo K, et al. NOX2-ROS-HIF-1α signaling is critical for the inhibitory effect of oleanolic acid on rectal cancer cell proliferation[J]. Biomed Pharmacother, 2017, 85: 733-739. DOI: 10.1016/j.biopha.2016.11.091. pmid: 27938946
[22]	Waghela BN, Vaidya FU, Pathak C. Upregulation of NOX-2 and Nrf-2 promotes 5-fluorouracil resistance of human colon carcinoma (HCT-116) cells[J]. Biochemistry (Mosc), 2021, 86(3): 262-274. DOI: 10.1134/S0006297921030044. pmid: 33838628
[23]	Yang WH, Huang Z, Wu J, et al. A TAZ-ANGPTL4-NOX2 axis regulates ferroptotic cell death and chemoresistance in epithelial ovarian cancer[J]. Mol Cancer Res, 2020, 18(1): 79-90. DOI: 10.1158/1541-7786.MCR-19-0691.
[24]	Yang WH, Chi JT. Hippo pathway effectors YAP/TAZ as novel determinants of ferroptosis[J]. Mol Cell Oncol, 2019, 7(1): 1699375. DOI: 10.1080/23723556.2019.1699375.
[25]	Wang N, Song L, Xu Y, et al. Loss of scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling[J]. EBioMedicine, 2019, 47: 65-77. DOI: 10.1016/j.ebiom.2019.08.057. pmid: 31495720
[26]	Zhan Y, Chen Q, Song Y, et al. Berbamine hydrochloride inhibits lysosomal acidification by activating Nox2 to potentiate chemotherapy-induced apoptosis via the ROS-MAPK pathway in human lung carcinoma cells[J]. Cell Biol Toxicol, 2023, 39(4): 1297-1317. DOI: 10.1007/s10565-022-09756-8.
[27]	Zhao L, Chen X, Feng Y, et al. COX7A1 suppresses the viability of human non-small cell lung cancer cells via regulating autophagy[J]. Cancer Med, 2019, 8(18): 7762-7773. DOI: 10.1002/cam4.2659.
[28]	Liu Y, Han D, Ma Q, et al. Prognostic value of NOX2 as a potential biomarker for lung adenocarcinoma using TCGA and clinical validation[J]. Mol Med Rep, 2023, 27(2): 48. DOI: 10.3892/mmr.2023.12935.
[29]	Shimizu H, Katsurahara K, Inoue H, et al. NADPH oxidase 2 has a crucial role in cell cycle progression of esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2022, 29(13): 8677-8687. DOI: 10.1245/s10434-022-12384-5.
[30]	Hu Y, Ye X, Wang R, et al. Current research progress in the role of reactive oxygen species in esophageal adenocarcinoma[J]. Transl Cancer Res, 2021, 10(3): 1568-1577. DOI: 10.21037/tcr-19-1985. pmid: 35116481

NADPH氧化酶2在恶性肿瘤中的研究进展

Research progress of NADPH oxidase 2 in malignant tumors

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 30

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘娜, 寇介丽, 杨枫, 刘桃桃, 李丹萍, 韩君蕊, 杨立洲. 血清miR-106b-5p、miR-760联合低剂量螺旋CT诊断早期肺癌的临床价值[J]. 国际肿瘤学杂志, 2024, 51(6): 321-325.
[2]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[3]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[4]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[5]	陈红健, 张素青. 血清miR-24-3p、H2AFX与肝癌患者临床病理特征及术后复发的关系研究[J]. 国际肿瘤学杂志, 2024, 51(6): 344-349.
[6]	郭泽浩, 张俊旺. PFDN及其亚基在肿瘤发生发展中的作用[J]. 国际肿瘤学杂志, 2024, 51(6): 350-353.
[7]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[8]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[9]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[10]	张蕊, 褚衍六. 基于FIT与肠道菌群的结直肠癌风险评估模型的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 370-375.
[11]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[12]	王丽, 刘志华, 杨伟洪, 蒋凤莲, 李全泳, 宋浩杰, 鞠文东. ROS1突变肺腺鳞癌合并脑梗死为主要表现的Trousseau综合征1例[J]. 国际肿瘤学杂志, 2024, 51(6): 382-384.
[13]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[14]	刘静, 刘芹, 黄梅. 基于SMOTE算法的食管癌放化疗患者肺部感染的预后模型构建[J]. 国际肿瘤学杂志, 2024, 51(5): 267-273.
[15]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.